{
    "clinical_study": {
        "@rank": "146194", 
        "arm_group": [
            {
                "arm_group_label": "NB + CLI", 
                "arm_group_type": "Experimental", 
                "description": "Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)"
            }, 
            {
                "arm_group_label": "Usual Care", 
                "arm_group_type": "Other", 
                "description": "Usual care (self-directed lifestyle intervention)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Phase 3b study is to assess the effects of combination therapy with\n      naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle\n      intervention (CLI) and in a manner consistent with its intended use after marketing\n      approval, on body weight and cardiovascular risk factors compared to the effects of Usual\n      Care in subjects who are overweight with dyslipidemia and/or controlled hypertension or\n      obese. At Week 26, subjects originally assigned to Usual Care switch to treatment with NB\n      and CLI, and subjects assigned to NB and CLI continue treatment for the duration of the\n      study (78-weeks treatment period)."
        }, 
        "brief_title": "Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects", 
        "condition": [
            "Obesity", 
            "Overweight"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Body Weight", 
                "Obesity", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or male, 18 to 60 years old\n\n          -  Body mass index (BMI) \u226530 kg/m2 and \u226445 kg/m2 for subjects with uncomplicated\n             obesity, or BMI \u226527 kg/m2 and \u226445 kg/m2 for subjects with dyslipidemia and/or\n             controlled hypertension\n\n        Exclusion Criteria:\n\n          -  History of type 1 or type 2 diabetes mellitus diagnosis\n\n          -  Myocardial infarction within 6 months prior to screening\n\n          -  Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading\n             scheme\n\n          -  Clinical history of large vessel cortical strokes, including ischemic and hemorrhagic\n             strokes (i.e., transient ischemic attack is not exclusionary)\n\n          -  History (within the last 20 years) of seizures, cranial trauma, bulimia, anorexia\n             nervosa, or other conditions that predispose subjects to seizures\n\n          -  Past or planned surgical or device intervention (e.g., gastric banding) for obesity\n\n          -  Chronic use or positive screen for opioids\n\n          -  Regular use of tobacco products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764386", 
            "org_study_id": "NB-404"
        }, 
        "intervention": [
            {
                "arm_group_label": "NB + CLI", 
                "description": "Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)", 
                "intervention_name": "NB", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NB + CLI", 
                "description": "The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.", 
                "intervention_name": "CLI", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Usual Care", 
                "description": "Usual Care is a self-directed lifestyle intervention program", 
                "intervention_name": "Usual Care", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Bupropion"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "obesity, overweight", 
        "lastchanged_date": "February 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80239"
                    }, 
                    "name": "Radiant Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63151"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cary", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27518"
                    }, 
                    "name": "PMG Research of Raleigh"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hickory", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28601"
                    }, 
                    "name": "PMG Research of Winston-Salem"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27609"
                    }, 
                    "name": "PMG Research of Raleigh"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28144"
                    }, 
                    "name": "PMG Research of Salisbury"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28401"
                    }, 
                    "name": "PMG Research of Wilmington, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44311"
                    }, 
                    "name": "Radiant Research-Akron"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anderson", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29621"
                    }, 
                    "name": "Radiant Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29651"
                    }, 
                    "name": "Radiant Research, Greer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "PMG Research of Charleston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37620"
                    }, 
                    "name": "PMG Research of Bristol"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Radiant Research Dallas-North"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84107"
                    }, 
                    "name": "Radiant Research, SLC"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)", 
        "other_outcome": [
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 5% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 10% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 15% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess effect of intended clinical method of use 32 mg naltrexone SR/360 mg bupropion SR in conjunction with a comprehensive lifestyle intervention (CLI) compared to Usual Care (minimal lifestyle intervention program) on percent change in body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the absolute change in body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including waist circumference", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting triglycerides", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in heart rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including fasting insulin", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including homeostasis model assessment - insulin resistance (HOMA-IR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including eating behavior", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including sexual function", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including weight-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52, Baseline to Week 78"
            }
        ], 
        "overall_official": {
            "affiliation": "Orexigen Therapeutics, Inc", 
            "last_name": "Senior Vice President, Head of Global Development", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess effect of intended clinical method of use 32 mg naltrexone SR/360 mg bupropion SR in conjunction with a comprehensive lifestyle intervention (CLI) compared to Usual Care (minimal lifestyle intervention program) on percent change in body weight", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 5% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the absolute change in body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including waist circumference", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including eating behavior", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 10% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on the percentage of subjects achieving a loss of at least 15% of baseline body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting triglycerides", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting LDL cholesterol", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in cardiovascular risk factors including fasting HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in heart rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including fasting insulin", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in measures of glucose metabolism including homeostasis model assessment - insulin resistance (HOMA-IR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including sexual function", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }, 
            {
                "measure": "To assess the effect of NB and CLI compared to Usual Care on changes in patient reported outcomes including weight related quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 26"
            }
        ], 
        "source": "Orexigen Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orexigen Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}